Abuse-deterrent properties do not prevent or reduce the risk of addiction¹

Formulated with RESISTEC™ technology

RESISTEC: Purdue Pharma's proprietary extended-release solid oral dosage formulation platform²

RESISTEC uses a unique combination of polymer and processing that:

• Confers tablet hardness²
• Imparts viscosity when dissolved in aqueous solutions²

Tablets manufactured using Purdue's RESISTEC technology contain polyethylene oxide in combination with the active ingredient and other excipients as needed for tablet manufacture.²

• In each Hysingla ER tablet, the sole active ingredient, hydrocodone bitartrate, is dispersed within a polyethylene oxide (PEO) polymer matrix
• This matrix is composed of long molecular chains that ensure the tablet does not readily dissolve in water
• The PEO polymer undergoes a proprietary manufacturing process that includes pressure, heat and time
• The process transforms the molecular chains into a firm, interlocked matrix that makes the tablets very hard